Your browser is no longer supported. Please, upgrade your browser.
SpringWorks Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.08 Insider Own4.50% Shs Outstand43.30M Perf Week-2.89%
Market Cap3.56B Forward P/E- EPS next Y-2.68 Insider Trans-56.04% Shs Float38.35M Perf Month1.28%
Income-45.60M PEG- EPS next Q-0.51 Inst Own84.40% Short Float10.62% Perf Quarter-13.22%
Sales35.00M P/S101.64 EPS this Y10.50% Inst Trans-5.82% Short Ratio11.60 Perf Half Y15.24%
Book/sh12.87 P/B5.53 EPS next Y-20.70% ROA-12.30% Target Price110.25 Perf Year134.00%
Cash/sh10.17 P/C7.00 EPS next 5Y- ROE-12.80% 52W Range29.41 - 96.48 Perf YTD-1.88%
Dividend- P/FCF- EPS past 5Y- ROI-8.30% 52W High-26.24% Beta-
Dividend %- Quick Ratio29.20 Sales past 5Y- Gross Margin- 52W Low141.96% ATR4.39
Employees56 Current Ratio29.20 Sales Q/Q- Oper. Margin- RSI (14)48.87 Volatility5.50% 6.16%
OptionableYes Debt/Eq0.01 EPS Q/Q167.90% Profit Margin- Rel Volume0.98 Prev Close68.44
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume351.31K Price71.16
Recom2.00 SMA20-0.11% SMA50-2.47% SMA20010.91% Volume345,850 Change3.97%
Jan-19-21Reiterated H.C. Wainwright Buy $87 → $101
Oct-29-20Reiterated H.C. Wainwright Buy $58 → $73
May-05-20Initiated Barclays Overweight $48
Mar-19-20Upgrade H.C. Wainwright Neutral → Buy $40 → $60
Mar-04-20Downgrade H.C. Wainwright Buy → Neutral $40
Jan-21-20Reiterated H.C. Wainwright Buy $34 → $40
Dec-04-19Initiated H.C. Wainwright Buy
Oct-08-19Initiated Wedbush Outperform $33
Oct-08-19Initiated JP Morgan Overweight $32
Oct-08-19Initiated Goldman Buy $37
Oct-08-19Initiated Cowen Outperform
May-06-21 06:30AM  
Apr-12-21 08:30AM  
Apr-05-21 08:18AM  
Apr-01-21 09:17AM  
Mar-28-21 12:44PM  
Mar-22-21 06:30AM  
Mar-12-21 06:07PM  
Mar-08-21 06:22AM  
Feb-25-21 08:16AM  
Feb-22-21 06:30AM  
Feb-04-21 06:30AM  
Jan-05-21 06:30AM  
Dec-19-20 02:44PM  
Dec-17-20 01:43PM  
Dec-15-20 09:00AM  
Dec-07-20 07:07AM  
Nov-24-20 06:30AM  
Nov-12-20 07:04AM  
Oct-26-20 07:30AM  
Oct-16-20 03:15PM  
Oct-13-20 04:05PM  
Oct-12-20 08:50AM  
Oct-07-20 08:25PM  
Oct-06-20 04:22PM  
Oct-05-20 06:30AM  
Sep-22-20 04:05PM  
Sep-21-20 07:00AM  
Sep-18-20 06:30AM  
Sep-16-20 06:30AM  
Sep-14-20 06:30AM  
Aug-12-20 04:45PM  
Aug-04-20 06:30AM  
Jul-22-20 06:30AM  
Jun-28-20 04:53PM  
Jun-22-20 09:00AM  
Jun-17-20 08:30AM  
Jun-10-20 06:14AM  
Jun-02-20 06:30AM  
May-26-20 06:30AM  
May-12-20 07:30AM  
Apr-15-20 02:49PM  
Mar-18-20 06:30AM  
Mar-12-20 04:30PM  
Feb-27-20 07:14AM  
Feb-18-20 06:30AM  
Jan-13-20 06:00AM  
Jan-06-20 06:30AM  
Dec-16-19 04:38PM  
Dec-13-19 10:07AM  
Dec-09-19 10:00AM  
Nov-12-19 08:00AM  
Oct-24-19 06:30AM  
Sep-27-19 08:00PM  
Sep-24-19 06:30AM  
Sep-17-19 04:05PM  
Sep-13-19 04:12PM  
Sep-12-19 06:15PM  
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SQUINTO STEPHEN PDirectorApr 28Sale76.2019,2311,465,437125,728Apr 28 08:18 PM
SQUINTO STEPHEN PDirectorApr 27Sale75.0520115,085144,959Apr 28 08:18 PM
Islam SaqibChief Executive OfficerApr 20Sale66.3924,0751,598,279884,052Apr 20 06:51 PM
Islam SaqibChief Executive OfficerApr 19Sale69.0438,4252,652,827908,127Apr 20 06:51 PM
SQUINTO STEPHEN PDirectorApr 15Sale75.011,05779,291145,160Apr 19 06:07 AM
SQUINTO STEPHEN PDirectorApr 14Sale75.0851138,365146,217Apr 19 06:07 AM
Smith L. MaryChief Development OfficerApr 13Option Exercise2.3010,00023,000177,511Apr 13 08:21 PM
Smith L. MaryChief Development OfficerApr 13Sale68.0710,000680,723167,511Apr 13 08:21 PM
Bain Capital Life Sciences Inv10% OwnerMar 09Sale71.501,450,000103,675,0005,831,307Mar 11 04:30 PM
ORBIMED ADVISORS LLC10% OwnerMar 01Sale83.191,220,000101,491,8006,186,307Mar 03 06:55 PM
Edris BadreddinChief Operating OfficerJan 25Sale84.0732,0002,690,282261,542Jan 26 04:31 PM
Smith L. MaryChief Development OfficerJan 20Option Exercise2.2310,00022,267177,511Jan 21 04:31 PM
Smith L. MaryChief Development OfficerJan 20Sale78.7010,000787,016167,511Jan 21 04:31 PM
Islam SaqibChief Executive OfficerJan 20Sale78.752,199173,1801,222,997Jan 21 04:30 PM
Islam SaqibChief Executive OfficerJan 19Sale78.5460,3014,736,2091,225,196Jan 21 04:30 PM